A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
Status:
Recruiting
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
A first-in-human clinical trial to test the investigational treatment ONCT-534 in
participants with metastatic castration-resistant prostate cancer. The main questions it aims
to answer are:
- What are the most tolerable doses of ONCT-534? (Phase 1)
- Does ONCT-534 have anti-tumor activity at tolerable doses? (Phase 2)
This is a dose escalation and expansion study where participants will receive daily oral
doses of ONCT-534.